The first and only body-identical HRT for post-menopausal oestrogen deficiency, Bijuve, has been passed by the SMC as suitable for use by Scotland’s National Health Service, after being adv
Armed with new phase 3 data, Bayer has started to prepare for filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin